Pfizer: Patient Preference Database Blueprint – Request for Proposals

Well-being, Health and Biomedical Discovery


Academic Unit: Inquire within your unit

Memorial Deadline: Tuesday 27th, July 2021

External Deadline: Monday 2nd, August 2021


Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Pfizer’s GMG competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the research gaps as outlined in the specific RFP.

For all general research grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. Pfizer must not be involved in any aspect of study protocol or project development, nor the conduct or monitoring of the research program.

Specific Area of Interest: This Innovation Challenge RFP seeks to solicit proposals to develop a blueprint for collating, organizing, and storing publicly available results from multiple patient preference studies such as may be found in publications or study reports in a single database, organizing results by disease, treatment class (JAK inhibitors in multiple diseases), patient type, etc. or any other categorization scheme and propose a method for extracting and synthesizing available data so that the existing quantitative preference estimates can be used as weights in decision-analytic models as an alternative to de novo primary data collection. The preference results in the database can be the result of any stated preference method (e.g., discrete-choice experiment, threshold technique, swing weighting, etc.) that provides quantitative estimates of marginal utility or relative importance of multiple disease and treatment attributes.

This is not meant to just be a catalog of existing publications. The ultimate end goal is a searchable database that allows interested parties to extract quantitative data on patient preferences based on an inputted query.

Key Dates

  • June 8, 2021 – RFP released
  • August 2, 2021 – Proposals due
  • September 2021 – Applicants notified; proposal chose
  • January 2022 – Resulting blueprint submitted to Pfizer

Additional information can be found here.

Funding Sources

Pfizer Inc

This opportunity was posted by: RGCS

Last modified: June 15, 2021